CBLT Updates on Omni’s Progress at Northshore Gold

CBLT.v, gold

As previously announced on August 19, 2020, CBLT Inc. (TSXV: CBLT) (“CBLT“) closed the sale of its majority interest in the Northshore Gold Property Joint Venture (the “Property“) to Omni Commerce Corp. (“Omni“). CBLT was paid $350,000 in cash and $1,100,000 in common shares of Omni, which shares are subject to a regulatory four month hold and a voluntary escrow agreement providing for staggered releases over the next year. The first release from escrow of 25% of CBLT’s holdings will take place on or about December 20, 2020. read more

Renforth Identifies Surimeau Project, with ~19km Polymetallic Mineralized Trend

RFR.C, Renforth Resopurces, gold, Quebec

Renforth Resources Inc. (CSE:RFR)(OTC PINK:RFHRF)(WKN:A2H9TN) (“Renforth” or the “Company”) has completed our June field work successfully and is particularly impressed with the results of our initial prospecting work at Malartic West, results will be released as available. read more

FSD Pharma Reports Favorable Topline Results from Phase 1 First-in-Human Safety and Tolerability Study of Ultramicronized PEA

All subjects completed the trial per protocol, no safety concerns found up to the highest dose tested of 2400 mg/day
C.HUGE, FSD Pharma, cannabis, pot

FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) (FRA: 0K9A) (“FSD Pharma” or the “Company”) today announced favorable topline results from its Phase 1 randomized, double-blind, placebo-controlled study of ultramicronized palmitoylethanolamide (PEA), or FSD201. This single-site study was conducted at the Alfred Hospital, part of the Alfred Health group of hospitals serving the state of Victoria in Australia and enrolled 48 healthy adult men and women. read more

FSD Pharma Announces Closing of C$10.125 Million Private Placement to Institutional Investors

C.HUGE, FSD Pharma, cannabis, pot

FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE.CN) (FRA: 0K9A) (the “Company”) announces the closing of a previously announced private placement of 1,500,000 of the Company’s Class B Subordinate Voting Shares (“Shares”) at a price of C$6.75 per Share and warrants to purchase 1,500,000 Shares (cumulatively, the “Securities”) of the Company to certain institutional investors for gross proceeds, before deducting placement fees and other estimated offering expenses payable by the Company, of approximately C$10.125 million. The warrants have a five-year term and an exercise price of C$9.65 per share. read more

FSD Pharma Inc. Announces C$10.125 Million Private Placement

C.HUGE, FSD Pharma, cannabis, pot

FSD Pharma Inc. (NASDAQ: HUGE) CSE;HUGE or the “Company”), today announced it has entered into definitive agreements with certain institutional investors for the purchase and sale of 1,500,000 shares of the Company’s Class B Subordinate Voting Shares (“Shares”) at a price of C$6.75 per Share pursuant to a private placement resulting in gross proceeds of approximately C$10.125 million. The Company has also agreed to issue common share purchase warrants to purchase 1,500,000 Shares of the Company. The warrants will have a five year-term and an exercise price of C$9.65 per share. The closing of the offering is expected to occur on or about June 8, 2020, subject to the satisfaction of customary closing conditions including applicable exchange approvals.  The Company has granted the investors an option to acquire up to an additional C$10.125 million of units on the terms set forth above for a period of 30 days following the initial closing. read more

FSD Pharma Receives U.S. FDA Approval to design a Phase 2a Clinical Trial to Treat Patients with Suspected or Confirmed COVID-19 Diagnosis

C.HUGE, FSD Pharma, cannabis, pot

FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) (FRA: 0K9A) (“FSD Pharma” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has given the company permission to submit an Investigational New Drug Application (IND) for the use of FSD-201 (ultramicronized palmitoylethanolamide, or ultramicronized PEA)  to treat COVID-19, the disease caused by the SARS-CoV-2 virus. Severe COVID-19 is characterized by an over-exuberant inflammatory response that may lead to a cytokine storm and ultimately death. FSD Pharma is focused on developing FSD-201 for its anti-inflammatory properties to avoid the cytokine storm associated with acute lung injury in hospitalized COVID-19 patients. read more

Renforth Commences Metallurgical Testing on New Alger Gold Project

RFR.C, Renforth Resopurces, gold, Quebec

 Renforth Resources Inc. (CSE:RFR)(OTC PINK:RFHRF) (WKN – A2H9TN) (“Renforth” or the “Company”) is pleased to announce that SGS Lakefield has been retained to determine the basic metallurgical response of a sample from New Alger’s Discovery Veins to standard processing for the recovery of contained gold and silver through tests which will include Head analysis, Mineralogy, Bond index test, Gravity separation and Cyanide leaching on gravity tailing. The sample which has been submitted for analysis is approximately 30kg of reject material from channels cut by Renforth in the largest historic blast area on the Discovery Veins. read more

Renforth Releases New Alger Gold Mineral Resource Estimate

RFR.C, Renforth Resopurces, gold, Quebec

Renforth Resources Inc. (CSE:RFR)(OTC PINK:RFHRF)(WKN – A2H9TN) (“Renforth” or the “Company”) is pleased to provide shareholders with a pit constrained gold Mineral Resource Estimate for Renforth’s wholly owned New Alger Property, located on the Cadillac Break, in Cadillac, Quebec, contiguous to the historic O’Brien Mine and the LaRonde Mine. This Mineral Resource Estimate has been calculated by P&E Mining Consultants Inc. of Brampton, Ontario, with an effective date of April 30th, 2020, using only assay data from between 2007 and the first hole (of four in that program) drilled by Renforth at New Alger earlier this year. Renforth has in its possession all the core from 2007 to date. read more

Deepest Gold Zone Intersected to Date at Renforth’s Wholly Owned New Alger Gold Property in Mine Vein #3

RFR.C, Renforth Resopurces, gold, Quebec
  • Deepest gold mineralization drilled to date at New Alger in REN-20-40 which intersected 6.3m of 1.46 g/t Au in the #3 vein at a vertical depth of 410m
  • Mine area veins exhibit high grade nugget effect again, with the most recent interval obtained of 32.33 g/t Au over 0.4m in REN-20-39
  • Mine area veins also continue to display the “halo” effect unique to the mineralization at New Alger, where alteration with a generally lower grade of gold adds width to the zone, such as REN-20-39 where Vein #1 intersected 0.71 g/t Au over a width of 17.4m, including 3.5m within this interval which graded 1.23 g/t Au.

PICKERING, ON / ACCESSWIRE / April 15, 2020 / Renforth Resources Inc. (CSE:RFR)(OTCPINK:RFHRF)(WKN:A2H9TN) (“Renforth” or the “Company”) is pleased to announce results from the final three holes drilled at New Alger in February/March 2020, each of which intersected gold as anticipated in the mine area veins. This successful campaign resulted in deeper pierce points than the bulk of the previous drilling at New Alger, extending the mine area veins down dip. The mine area veins are hosted within the Piché volcanics, on the south side of the Cadillac Break. The entire mineralized system, which strikes for approximately 1.4kms on the New Alger property, is open at depth. The Cadillac Mining Camp is regarded as “essentially unexplored beyond a depth of 400 metres. The gold potential of this considerable volume of rock remains to be confirmed”, as published in The deep-seated gold potential of the Cadillac Mining Camp published in PRO 2005-02 by Géologie Quebec. This statement holds true for Renforth’s New Alger property and provides management with focus. read more

Renforth Commences Metallic Screen Study at Parbec

RFR.C, Renforth Resopurces, gold, Quebec

Renforth Resources Inc. (CSE – RFR) (OTC Pink – RFHRF) (WKN – A2H9TN) (“Renforth” or the “Company”) would like to inform shareholders that initial test metallic screening at Parbec has returned higher coarse gold values in each sample tested. Due to these results a broader metallic screen study has commenced on our wholly owned Parbec property. read more